Omnicell, Inc. (OMCL) Position Raised by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC raised its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 47.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 434,422 shares of the company’s stock after buying an additional 139,069 shares during the period. Rice Hall James & Associates LLC’s holdings in Omnicell were worth $18,724,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of OMCL. Bank of America Corp DE boosted its position in Omnicell by 79.7% in the first quarter. Bank of America Corp DE now owns 202,466 shares of the company’s stock worth $8,231,000 after buying an additional 89,817 shares during the last quarter. First National Bank of Omaha acquired a new position in Omnicell during the first quarter worth about $865,000. Parametric Portfolio Associates LLC boosted its position in Omnicell by 4.9% in the first quarter. Parametric Portfolio Associates LLC now owns 145,279 shares of the company’s stock worth $5,906,000 after buying an additional 6,786 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Omnicell during the fourth quarter worth about $788,000. Finally, Nationwide Fund Advisors boosted its position in Omnicell by 0.9% in the first quarter. Nationwide Fund Advisors now owns 253,955 shares of the company’s stock worth $10,323,000 after buying an additional 2,224 shares during the last quarter. Institutional investors own 96.35% of the company’s stock.
Shares of Omnicell, Inc. (NASDAQ OMCL) opened at 50.10 on Friday. The stock’s market capitalization is $1.88 billion. Omnicell, Inc. has a one year low of $30.35 and a one year high of $51.98. The firm has a 50 day moving average price of $45.37 and a 200 day moving average price of $41.17.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.08 million. During the same period in the previous year, the firm posted $0.38 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. Analysts predict that Omnicell, Inc. will post $1.31 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/omnicell-inc-omcl-position-raised-by-rice-hall-james-associates-llc/1478103.html.
A number of equities analysts recently issued reports on OMCL shares. Zacks Investment Research cut Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. ValuEngine upgraded Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. CIBC boosted their price objective on Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, April 26th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $47.00 price objective on shares of Omnicell in a report on Tuesday, July 25th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Omnicell currently has an average rating of “Buy” and an average price target of $49.00.
In related news, Director Gary S. Petersmeyer sold 2,200 shares of Omnicell stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $41.41, for a total value of $91,102.00. Following the completion of the transaction, the director now directly owns 21,075 shares in the company, valued at $872,715.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Randall A. Lipps sold 40,000 shares of Omnicell stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.76, for a total value of $1,990,400.00. Following the completion of the transaction, the chairman now owns 196,551 shares of the company’s stock, valued at $9,780,377.76. The disclosure for this sale can be found here. Insiders sold 199,823 shares of company stock valued at $9,301,391 over the last ninety days. Insiders own 3.77% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.